

CASE REPORT

Open Access



Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review

Tsukasa Masuda¹, Takeo Kosaka^{1*} , Kohei Nakamura², Hiroshi Hongo¹, Kazuyuki Yuge¹, Hiroshi Nishihara² and Mototsugu Oya¹

Abstract

Background: Prostate cancer (PC) is mainly known to metastasize to bone, lung and liver, but isolated metastases of prostate cancer, including ductal carcinoma, in the urinary tract are very rare. We describe two patients with nodular masses in the urinary tract (the anterior urethra or the urinary bladder) that were found on cystoscopy during treatment of castration-resistant prostate cancer.

Case presentation: In both cases, the pathological diagnosis from transurethral tumor resection showed that they were androgen indifferent prostate cancer (AIPC), including aggressive variant prostate cancer (AVPC) in Case 1 and treatment-induced neuroendocrine differentiation prostate cancer (NEPC) in Case 2. In Case 1, Loss of genetic heterozygosity (LOH) of *BRCA2* and gene amplification of *KRAS* was identified from the urethra polyps. In Case 2, homozygous deletion was observed in *PTEN*, and LOH without mutation was observed in *RB1*.

Conclusion: These are the first reports of two cases of urinary tract metastasis of AIPC.

Keywords: Neuroendocrine differentiation prostate cancer, Urinary tract metastasis, *AR*, *TP53*, *BRCA2*, *PTEN*, Aggressive variant prostate cancer

Background

Prostate cancer (PC) primarily metastasizes to bone, lung, and liver. Reported cases of metastases in the anterior urethra or bladder are rare, including only 15 cases of anterior urethra metastasis. Furthermore, androgen indifferent prostate cancer (AIPC), the pathological characteristics of which have increasingly been described, [1, 2] often metastasizes to similar sites, but there are no reports of urinary tract metastasis. We report two cases involving AIPC metastasis to the urinary tract, describe

the genomic sequence, and discuss the potential mechanism of metastasis to the urinary tract.

Case presentation

Case 1. A 79 years-old man presented with obstructive lower urinary tract symptoms at another hospital. His prostate-specific antigen (PSA) level was 15.54 ng/mL. Pathological diagnosis from transrectal needle biopsy was adenocarcinoma with a Gleason Score of 5 + 5. Staging computed tomography (CT) scan showed regional lymph node (LN) metastases. He received combined androgen blockade (CAB) therapy initially, but after a decrease in PSA, his levels eventually increased. He was diagnosed with castration-resistant prostate cancer (CRPC) and began


*Correspondence: takemduro@gmail.com

¹Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
Full list of author information is available at the end of the article



enzalutamide but despite continuous treatment for 6 months, chemotherapy was required. However, although chemotherapy initially lowered his PSA, eventually it increased a lot subsequently. He had difficulty urinating smoothly because of disease progression-related obstruction requiring clean intermittent catheterization. Subsequently, he received abiraterone but it was ineffective. Three years after

the original diagnosis, he was referred to our hospital for further treatment of CRPC. He had bloody urine and difficulty with self-catheterization for 5 months after starting. Cystoscopy showed several nodular polyps in the penile urethra (Fig. 1a and b). Magnetic resonance imaging (MRI) demonstrated that the tumor had grown to 8 cm in diameter and invaded the rectum (Fig. 1c). MRI also showed metastases



of the prostate cancer extended with skip lesions along the corpus spongiosum in the entire anterior urethra (Fig. 1d). Moreover, he developed a catheter obstruction caused by hematuria, so a suprapubic cystostomy tube was placed and transurethral resection of the prostate (TURP) was performed to achieve tumor bleeding coagulation. Simultaneously, he underwent endoscopic resection of the urethra polyps. Histology showed metastasis of prostatic adenocarcinoma with aggressive variant (Fig. 1e, f, g, and h); particularly, as illustrated in Fig. 1e and f with immunolabeling for hematoxylin and eosin staining, the pathological findings of Case 1 exhibited a high-grade tumor defined by characteristic nuclear features, including lack of prominent nucleoli and high nuclear to cytoplasmic ratio. He was treated using cisplatin and etoposide. After two cycles, he achieved a progressive disease and he was treated with the best supportive care.

Targeted next-generation sequencing using an in-house assay of the resected specimen from the urethra polyps was performed (Additional file 1). A *TP53* somatic point mutation (p.H193Y) was detected as a pathogenic variant. Gene amplification was detected in androgen receptor (*AR*) and *KRAS* (estimated copy number (CN): 35.3, 5.8, respectively). Loss of genetic heterozygosity (LOH) without mutation was observed in *BRCA2*. CN variation box (Fig. 1i) indicated a high LOH frequency, which is common in homologous recombination-deficient tumors.

Case 2. A 69 years old man was diagnosed with Gleason score 4+5 prostate cancer at another hospital. His serum PSA level was 81.5 ng/mL, and his clinical stage from CT and whole-body bone scans was T3aN1M1 (multiple lung and bone metastases). CAB therapy was started, and his PSA decreased to 0.36 ng/mL. However, after 1 year on androgen deprivation therapy (ADT), resistance to castration developed (PSA: 54.22 ng/mL), so docetaxel was started. For ten cycles of chemotherapy, his PSA decreased to a nadir of 17.2 ng/mL but subsequently increased to 84.0 ng/mL. MRI and CT of the abdomen and pelvis (Fig. 2a and b) showed non-muscle-invasive masses in the neck and urinary bladder posterior wall, although chest CT of the lung metastases showed partial responses (PRs). Cystoscopy showed bladder-neck obstruction by a tumor invading from the prostate gland (Fig. 2c) and revealed another group of nodular masses at the left posterior bladder wall (Fig. 2d). He was referred to our hospital for TURP and transurethral resection of the bladder


tumor because of hematuria and urinary obstructive symptoms. Both pathological diagnoses of the bladder neck and posterior wall showed neuroendocrine differentiation prostate cancer (NEPC) (Fig. 2e, f, g, and h). Specifically, high mitotic rate cells were detected using immunolabeling for H&E staining, as illustrated in Fig. 2e, and the signals of synaptophysin were found in over 50% tumor cells (Fig. 2h). From the abovementioned points, we identified Case 2 as treatment-induced NEPC (tNEPC). He underwent two cycles of etoposide and carboplatin. However, the disease progressed, and the anticancer treatment was eventually discontinued.

Targeted next-generation sequencing of the resected specimen from the posterior bladder posterior wall identified a *TP53* somatic point mutation (p.R196P) as a pathogenic variant. Gene amplification was detected in *AR* (estimated CN: 25.4). Homozygous deletion was observed in *PTEN*, and LOH without mutation was observed in *RBI*. The CN variation box is shown in Fig. 2i.

Discussion and conclusion

Our two patients were initially diagnosed with prostate adenocarcinoma, which during hormonal treatment progressed with aggressive variant and neuroendocrine differentiation and multiple metastases to the urinary tract. NEPC occurs in 17% of patients with metastatic CRPC and has a poorer prognosis than other PCs [1, 3, 4]. NEPC tends to metastasize to bone, lung, and liver, and urethra or bladder metastasis has not been reported [1, 2]. Isolated metastasis or recurrence of PC in the intra-urinary tract is extremely rare, with only 15 cases reported previously [5–19] (Table 1); five had an origin in the prostatic ductal adenocarcinoma (PDC) and most of the rest were from adenocarcinomas with lower Gleason scores. On the other hand, in a study of 282 patients with secondary bladder neoplasms, 19% had PC-related secondary urinary bladder tumors [20], and 39% had urinary bladder metastases at autopsy [21], but the majority showed bladder-neck invasion. Case 2 may be the first report of adenocarcinoma with tNEPC as there are few case reports on isolated metastasis of PC to the bladder except for the bladder neck [22, 23].

From a genomic perspective, we wondered why these two cases progressed so quickly. Some patients with AIPC, including AVPC and tNEPC, respond to platinum-based combination chemotherapeutic regimens, but our patients were relatively treatment resistant. We actually performed targeted genomic sequencing of the formalin-fixed paraffin-embedded tumor specimens from TURP by applying algorithms previously reported [24, 25] and



identified the factors common between the two patients: *AR* amplification and *TP53* mutation (Figs. 1 and 2i). *AR* is overexpressed in most CRPC patients, and *AR* amplification means that these patients acquired castration resistance during cancer progression [26]. However, the fact was reported that in AIPC definition that the presence of *AR* amplification was irrelevant [2, 3]. In particular, our Case 1 patient showed *KRAS* amplification.

Although *KRAS* mutation may be an advanced prostate cancer biomarker [27], the importance of *KRAS* amplification is uncertain. Progression of metastatic prostate cancer previously was coupled with enhanced expression levels of enhancer of zeste homolog, which is synergized by activation of *KRAS* and *AR* overexpression [28]. In Case 1, *KRAS* amplification may have been associated with accelerated de-differentiation to intractable

Table 1 Systematic review of studies of urethral metastasis from prostate cancer cases

No. ref	Case	Age	Symptoms at the time of recurrence	PSA (ng/ml)	Location	Appearance (shape, number, size)	Treatment	Pathology	Possible causes
	<i>Our case (Case 1)</i>	79	<i>Hematuria with difficulty urinating</i>	841	<i>In the proximal penile urethra and distal bulbar urethra</i>	<i>Nodular, multiple</i>	<i>TUR</i>	<i>AVPC</i>	<i>CIC</i>
[5]	Britt Haller et al. [5]	67	Painless hematuria	1.5	Distal bulbar urethra and distal penile urethra in the navicular fossa	Papillary, several	Urethrectomy	PDC	Post TURP/EBRT (4 years)
[6]	Darren J. Bryk et al. [6]	83	Obstructive voiding symptoms	0.67	From the penile to the membranous urethra	Papillary, multiple	Biopsies	PC	Post brachytherapy (9 years)
[7]	Yong G Wang et al. [7]	66	Painless hematuria	0.13	In the anterior bulbar urethra	Papillaey, single	TUR	PDC	Post radiation (4 years)
[8]	Hansan Jhaveri et al. [8]	82	Hematuria and urethral bleeding with difficulty urinating	0.26	From the prostatic urethra past the membranous urethra	A large mass, single	No invasive treatments	PC	Direct extension
[9]	Ibrahim Zardawi et al. [9]	84	Urinary retention and symptoms of urinary tract infection	10.3	One of the lesions in the membranous urethra, two in the bulbar and penile urethra	Polyp, three lesions	TUR	PC	Post TURP (3 years)
[11]	Darren Beiko et al. [11]	68	Gross hematuria	0.7	In the midbulbous urethra	Polyp, single, 2 mm	Cold cup biopsy	PC	Post TURP/EBRT (4 years)
[10]	Enrique Gomez et al. [10]	68	LUTS and urethral bleeding	1.7	Between the distal bulbar urethra and proximal penile urethra	Nodular, single	TUR	PC	Post radiation (4 years)
[12]	Chi-Feng Hung et al. [12]	77	Voiding straining and a bifurcated voiding stream	5.02	8 cm from the meatus and 2 cm distal to the bulbous urethra	Nodular, single	TUR	PC	Venous spread
[13]	Jutin M. Green et al. [13]	74	Painless hematuria	1.25	In the entire anterior urethra, including the fossa navicularis	Papillary, multiple	TUR	PDC	Post radiation (5 years)
[14]	G. Nabi et al. [14]	65	Gross hematuria	12	In anterior urethra leading to stricture	Multiple nodules with ulcerations	TUR	PC	Post TURP (2 weeks)
[15]	C. Ohyama et al. [15]	71	Gross hematuria	5.2	On the distal urethra	Papillary, small	Chemotherapy TUR	PDC	Unidentified
[16]	T. Kobayashi et al. [16]	76	Gross hematuria	Normal	On the anterior urethra	Nonpapillary, sessile	TUR	PC	Post TURP
[17]	Graeme B Taylor et al. [17]	68	Gross painless hematuria	0.8	In the anterior penile urethra 4 cm from the external meatus	Papillary, single	TUR	PDC	Post TURP (3 years)
[18]	Faruk Aydin et al. [18]	84	A watery, bloody urethral discharge	-	The prostatic and anterior penile urethra	Papillary, single	TUR	PC	post TURP (2 years)
[19]	Narendra Kotecha et al. [19]	64	Intermittent spotting of blood	-	In the pendulous urethra, approximately 2.5 cm proximal to the urethral meatus	Papillary, single	TUR	PC	post TURP (2 years)

Italics to distinguish between the past cases and our case

PC Prostate cancer, PDC Prostate ductal carcinoma, AVPC Aggressive variant prostate cancer, CIC Clean intermittent catheterization, TUR Transurethral resection

NEPC. In Case 2, *RB1* loss co-occurred with *TP53* mutation. Previous studies have described that *TP53* mutation cooperated with *RB1* loss to confer an ADT-resistant phenotype, proposed as an aggressive variant prostate cancer [29, 30].

There are several hypotheses regarding the mechanisms of urethra metastasis, as in Case 1, including implantation following instrumentation or catheterization [11, 13]. Table 1 shows that previous patients with urethra metastasis had a history of post-TURP or prior radiotherapy for PC (or PDC), but our patient 1 did not respond. Additionally, because the tumor obstructed his urinary tract, he could not urinate smoothly with the self-catheter. Consequently, the mechanism for anterior urethra metastasis in Case 1 could have been direct surface implantation by self-catheterization. Regarding Case 2, it is probable that the mechanism of bladder metastasis was initial NEPC invasion of the bladder neck and subsequent posterior wall seeding. Metastasis from a urothelial carcinoma is well known, but the mechanism is unclear [31]. One hypothesis involves the seeding or intraepithelial spread of transformed cells [31, 32]. The spread from the primary tumor to the bladder wall in Case 2 may be similar to the spread of a urothelial carcinoma. These two cases also involved very interesting metastatic mechanisms.

Abbreviations

PC: Prostate cancer; AIPC: Androgen indifferent prostate cancer; AVPC: Aggressive variant prostate cancer; NEPC: Neuroendocrine differentiation prostate cancer; PSA: Prostate-specific antigen; CAB: Combined androgen blockade; CRPC: Castration-resistant prostate cancer; c-TURP: A channel transurethral resection of the prostate; AR: Androgen receptor; LOH: Loss of genetic heterozygosity; ADT: Androgen deprivation therapy; PDC: Prostatic ductal adenocarcinoma.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12920-022-01267-z>.

Additional file 1. How to perform the targeted next-generation sequencing using an in-house assay of the resected specimen.

Acknowledgements

Yoko Suzuki, Emmy Yanagida, and Hiroshi Yamada provided technical assistance.

Author contributions

All authors contributed to the diagnosis and treatment of the patient. TM and TK prepared the manuscript and figures. HH, KY, and MO edited the manuscript, substantively revised it. KN and HN analyzed and interpreted the data of targeted next-generation sequencing. All authors have approved the submitted version and agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work. All authors read and approved the final manuscript.

Funding

This study was supported in part by a Grant-in-Aid for Scientific Research (#20H03817 to T. Kosaka) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The study was supported in part by a research grant to T. Kosaka from the Fukuzawa Foundation of Keio University, Japan. The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The data of targeted next-generation sequencing in two cases have been deposited to the Genome Sequence Archive (GSA). The assigned accession number is HRA002209. (<https://bigd.big.ac.cn/gsa-human/browse/HRA002209>).

Declarations

Ethics approval and consent to participate

This study was approved by the Ethical Committee of Keio University Hospital (#20160084 and #20180015). Written informed consent was obtained from the participants.

Consent for publication

Written consent has been obtained from both of the patients for publication of clinical details, radiological and biological data.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. ²Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.

Received: 24 November 2021 Accepted: 10 May 2022

Published online: 21 May 2022

References

- Conteduca V, et al. Clinical features of neuroendocrine prostate cancer. *Eur J Cancer*. 2019;121:7–18.
- Berchuck JE, Viscuse PV, Beltran H, Aparicio A. Clinical considerations for the management of androgen indifferent prostate cancer. *Prostate Cancer Prostatic Dis*. 2021;24:623–37.
- Aggarwal R, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. *J Clin Oncol*. 2018;36:2492–503.
- Epstein JI, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. *Am J Surg Pathol*. 2014;38:756–67.
- Haller B, Yao HH-I, Christidis D, Chee J, Bishop C. Clinical recurrence of prostatic ductal adenocarcinoma in the anterior urethra. *J Clin Urol*. 2020. <https://doi.org/10.1177/2051415820921312>.
- Bryk DJ, Angermeier KW, Klein EA. A case of metastatic prostate cancer to the urethra that resolved after androgen deprivation therapy. *Urology*. 2019;129:e4–5.
- Wang YG, Davies N, Desai D, Yap H-W. Local control of isolated anterior urethral metastasis from ductal prostate cancer. *J Clin Urol*. 2017;10:309–10.
- Jhaveri H, Combs K, Jhaveri F. Direct extension of prostatic adenocarcinoma protruding through the urethral meatus. *Urol Case Rep*. 2017;13:13–5.
- Zardawi I, Chong P. Metastatic prostate cancer to the urethra masquerading as urothelial carcinoma. *Urol Case Rep*. 2016;7:33–6.
- Gómez Gómez E, Carrasco Aznar JC, Moreno Rodríguez Mdel M, Valero Rosa J, Requena Tapia MJ. Palliative surgery for rare cases of anterior urethral metastasis in prostate cancer. *Case Rep Urol*. 2014;2014:584957.
- Beiko D, Zaza K, Power KV, Siemens DR, Boag AH. Isolated anterior urethral recurrence of prostatic adenocarcinoma. *Can Urol Assoc J*. 2014;8:E361–363.

12. Hung CF, et al. Invasive adenocarcinoma of the prostate with urethral tumor. *J Chin Med Assoc.* 2010;73:101–3.
13. Green JM, Tang WW, Jensen BW, Orihuela E. Isolated recurrence of ductal prostate cancer to anterior urethra. *Urology.* 2006;68(428):e413–425.
14. Nabi G, Devinder S, Dogra RN, Dinda AK. Malignant anterior urethral strictures: a rare complication of transurethral resection of malignant prostate. *Int Urol Nephrol.* 2002;34:73–4.
15. Ohyama C, et al. Adenocarcinoma arising from the prostatic duct mimicking transitional cell carcinoma. *Int J Urol.* 2001;8:408–11.
16. Kobayashi T, et al. Isolated recurrence of prostatic adenocarcinoma to the anterior urethra after radical prostatectomy. *J Urol.* 2000;164:780.
17. Taylor GB, McNeal JE, Cohen RJ. Intraductal carcinoma of the prostate metastatic to the penile urethra: a rare demonstration of two morphologic patterns of tumor growth. *Pathology.* 1998;30:218–21.
18. Aydin F. Endometrioid adenocarcinoma of prostatic urethra presenting with anterior urethral implantation. *Urology.* 1993;41:91–5.
19. Kotecha N, Gentile RL. Carcinoma of prostate with urethral metastasis. *Urology.* 1974;3:85–6.
20. Bates AW, Baithun SI. Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases. *Histopathology.* 2000;36:32–40.
21. Saitoh H, et al. Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. *Cancer.* 1984;54:3078–84.
22. Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R. Multiple urinary bladder masses from metastatic prostate adenocarcinoma. *Rare Tumors.* 2010;2:e65.
23. Camilot D, Pizzolitto S, DeMaglio G, Falconieri G. Intravesical botryoid adenocarcinoma of the prostate: report of an unusual growth pattern of prostatic carcinoma simulating a urinary bladder tumor. *Ann Diagn Pathol.* 2007;11:413–6.
24. Mose LE, Wilkerson MD, Hayes DN, Perou CM, Parker JS. ABRA: improved coding indel detection via assembly-based realignment. *Bioinformatics.* 2014;30:2813–5.
25. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics.* 2009;25:1754–60.
26. Urbanucci A, et al. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. *Oncogene.* 2012;31:2153–63.
27. Wang XS, et al. Characterization of KRAS rearrangements in metastatic prostate cancer. *Cancer Discov.* 2011;1:35–43.
28. Cai H, et al. Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. *Cancer Res.* 2012;72:4672–81.
29. Ku SY, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. *Science.* 2017;355:78–83.
30. Nyquist MD, et al. Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. *Cell Rep.* 2020;31:107669.
31. Habuchi T. Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and clinical implications. *Int J Urol.* 2005;12:709–16.
32. Jones TD, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. *Clin Cancer Res.* 2005;11:6512–9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

